Cambridge has been chosen to host a new global forum designed to change the face of international healthcare.

Gamechanging innovation will be centre stage at the Next Health World Innovation Forum – a new international healthcare conference which takes place in Cambridge from June 26-27, 2019.

The Innovation Forum is partnering with Cambridge’s pioneering Milner Therapeutics Institute to challenge the status quo and identify technologies that will revolutionise patient care across a range of disease areas.

The event will incorporate the annual symposium of the Milner Institute, which is dedicated to transforming groundbreaking research into new therapies, by breaking down the barriers between academia and industry. 
Confirmed speakers include representatives from Servier, Pfizer, Innovative Medicines Initiative and Cancer Research UK. 

Key topics will include Machine learning and artificial intelligence in healthcare; Cancer; Neuroscience and neurotech; Cell and gene therapy; Prevention (diagnostics, monitoring); Evidence-based new economic models for healthcare; Nutrition, lifestyle and healthcare; Holistic approaches to medicine.

As well as pinpointing the gaps, challenges and unmet needs of the current global healthcare ecosystem, the forum is determined to define goals for the biopharma and healthcare industry, connect investment capital with biotech startups and identify strategies, policy and technological solutions that will enable a healthier future.

Cambridge was chosen as host city because of its world-class BioMedTech, research and academic cluster.

The partner hosts believe the event will unite leading stakeholders from across the global healthcare community, ranging from academics, large established bio-pharmaceutical and medical technology companies, healthcare providers and government representatives to clinicians and patient groups, disruptive startups and investors across all stages of the research and investment cycle. 

Professor Tony Kouzarides (pictured), director of the Milner Therapeutics Institute at the University of Cambridge, says: “The Milner Therapeutics Institute is excited to work with the Innovation Forum to create Next Health as the biggest biotech gathering in Europe.

“By partnering our annual symposium with this event, we will drive new opportunities for translational collaboration and change in healthcare.”

The meeting will feature prominent keynote speeches as well as ‘fireside’ chats, startup pitches to investors and panel and round table discussions led by senior decision makers from industry, academia and government.

Dr Marek Tyl, CEO of the Innovation Forum says: “The healthcare industry is just at the beginning of a revolutionary transformation and we aim to shape not just the debate but also tangible government, industry and academic initiatives to create more innovative but also more affordable and accessible, future healthcare that not only treats but also prevents disease.”

The Innovation Forum is a global network of more than 10,000 innovators that seeks to accelerate technology development by generating synergy between academia, industry, investment and the public sector. It focuses on the evolution of current and future technologies, ranging from those at the nascent stage to those on the cusp of commercial application.

The Milner Therapeutics Institute is a fully integrated Institute of the School of Biological Sciences and the School of Clinical Medicine at the University of Cambridge. 

Its mission is to connect academia and industry, enable collaborative research and accelerate therapeutic companies. It delivers this mission through a global therapeutic alliance of 74 industry and academic partners. 

The alliance consists of seven major pharmaceutical companies (Astex, AstraZeneca, Elysium Health, GlaxoSmithKline, Johnson & Johnson Innovation, Shionogi, Pfizer), three academic centres in Cambridge (University of Cambridge, Babraham Institute and Sanger Institute), 14 affiliated international institutions, two venture capital companies and 48 small and medium size companies that are technology or service providers or have drug development pipelines themselves. 

The Institute’s purpose-built research laboratories will open in January 2019 on the Cambridge Biomedical Campus and will house companies and academic scientists. 

• For more details visit nxthlth.com